Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older

Zostavax has been shown to be efficacious in the prevention of herpes zoster and generally well tolerated in clinical trials among subjects 60 years old or older. This prespecified combined analysis from two studies compares the levels of immunogenicity and safety of Zostavax in subjects 50 to 59 ye...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Sutradhar, Santosh C., Wang, William W. B., Schlienger, Katia, Stek, Jon E., Xu, Jin, Chan, Ivan S. F., Silber, Jeffrey L.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology (ASM) 2009
Teme:
Vaccine Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2681586/
https://ncbi.nlm.nih.gov/pubmed/19261769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00407-08
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki